Targeted combo offers hope for leukemia patients too sick for strong chemo

NCT ID NCT02677922

Ongoing Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Mar 11, 2026 · Last updated May 15, 2026 · Updated 12 times

Summary

This study tests two experimental drug combinations for adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (IDH-mutant AML) who cannot tolerate intensive chemotherapy. Participants receive either one of two oral targeted pills (AG-120 or AG-221) plus a standard injection (azacitidine), or azacitidine alone. The goal is to find the best dose and see if the combinations are safe and improve remission rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Local Institution - 102

Boston, Massachusetts, 02114, United States
Local Institution - 103

Chicago, Illinois, 60637, United States
Local Institution - 105

Duarte, California, 91010-301, United States
Local Institution - 106

New York, New York, 10065, United States
Local Institution - 107

New Haven, Connecticut, 06510, United States
Local Institution - 108

Chicago, Illinois, 60611, United States
Local Institution - 110

Dallas, Texas, 75390-85520, United States
Local Institution - 125

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 175

Melbourne, 3141, Australia
Local Institution - 177

Perth, 6000, Australia
Local Institution - 178

Adelaide, South Australia, SA 5000, Australia
Local Institution - 200

Paris, 75475, France
Local Institution - 201

Villejuif, 94805, France
Local Institution - 202

Pierre-Bénite, 69495, France
Local Institution - 203

Toulouse, 31059, France
Local Institution - 204

Pessac, 33604, France
Local Institution - 205

Lille, 59037, France
Local Institution - 206

Marseille, 13273, France
Local Institution - 225

Ulm, 89081, Germany
Local Institution - 227

Berlin, 12200, Germany
Local Institution - 230

Dresden, 01307, Germany
Local Institution - 250

Pesaro, 31122, Italy
Local Institution - 251

Orbassano, 10043, Italy
Local Institution - 252

Florence, 50134, Italy
Local Institution - 253

Bologna, Emilia-Romagna, 40138, Italy
Local Institution - 254

Padova, 35128, Italy
Local Institution - 255

Roma, 00189, Italy
Local Institution - 256

Genova, 16132, Italy
Local Institution - 277

Utrecht, 3584 CX, Netherlands
Local Institution - 327

Lisbon, 1169-050, Portugal
Local Institution - 350

Seoul, 138-736, South Korea
Local Institution - 351

Seoul, 135-710, South Korea
Local Institution - 375

Barcelona, 08907, Spain
Local Institution - 376

Cáceres, 10005, Spain
Local Institution - 377

Valencia, 46009, Spain
Local Institution - 378

Madrid, 28007, Spain
Local Institution - 379

Barcelona, 08036, Spain
Local Institution - 380

Málaga, 29010, Spain
Local Institution - 381

Madrid, 28033, Spain
Local Institution - 401

Zurich, 0, Switzerland
Local Institution - 403

Basel, 4031, Switzerland
Local Institution - 427

Headington, OX3 9DU, United Kingdom
Local Institution - 428

London, SE5 9RS, United Kingdom
Local Institution - 429

Birmingham, B15 2TH, United Kingdom
Local Institution - 430

Sutton (Surrey), SM2 5PT, United Kingdom
Local Institution - 902

Boston, Massachusetts, 02115, United States
Local Institution - UNK-121

Yvoir, 5530, Belgium
Local Institution - UNK-52

Gothenburg, 413 45, Sweden

Conditions

Explore the condition pages connected to this study.

LEUKEMIA, MYELOID, ACUTE